Inhibition of human cytochrome P450 activities by kava extract and kavalactones

Drug Metabolism and Disposition

Volumn 30, Issue 11, 2002, Pages 1153-1157

  Mathews, James M ^a   Etheridge, Amy S ^a   Black, Sherry R ^a  

^a RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DESMETHOXYYANGONIN; DIHYDROMETHYSTICIN; KAVA EXTRACT; KAVALACTONE; KAWAIN; LACTONE DERIVATIVE; METHYSTICIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; UNCLASSIFIED DRUG; YANGONIN; ENZYME INHIBITOR; ISOENZYME; KAVA; LACTONE; MIXED FUNCTION OXIDASE; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PLANT EXTRACT; PYRONE DERIVATIVE; RECOMBINANT PROTEIN;

ARTICLE; COMPLEX FORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG INTERACTION; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME; PRIORITY JOURNAL; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; IN VITRO STUDY; METABOLISM;

PIPER METHYSTICUM;

CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; ISOENZYMES; KAVA; LACTONES; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; NADP; PLANT EXTRACTS; PYRONES; RECOMBINANT PROTEINS;

EID: 0036842023     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.11.1153     Document Type: Article

References (30)

1. Almeida JC and Grimsley EW (1996) Coma from the health food store: Interaction between kava and alprazolam. Ann Intern Med 125:940-941.
2. American Botanical Council (2001) American Botanical Council Announces New Safety Information on Kava. http://www.herbalgram.org (Accessed March 13, 2002).
3. Blumenthal M, German Federal Institute for Drugs and Medical. Busse WR, Riggins C, and Rister R (1998) The Complete German Commission E Monographs: Therapeutic Guide to Herbal Medicines (trans Klein S). American Botanical Council, Boston.
4. Clarke SE. Baldwin SJ, Bloomer JC, Ayrton AD, Sozio RS, and Chenery RJ (1994) Lauric acid as a model substrate for the simultaneous determination of cytochrome P450 2E1 and 4A in hepatic microsomes. Chem Res Toxicol 7:836-842.
5. DerMarderosian A (1999) The Review of Natural Products by Facts and Comparisons. Wolters Kluwer Co., St. Louis, MO.
6. D'Souza DL, Levasseur LM, Nezamis J, Robbins DK, Simms L, and Koch KM (2001) Effect of alosetron on the pharmacokinetics of alprazolam. J Clin Pharmacol 41:452-454.
7. Elcombe CR, Bridges JW, Gray TJB, Nimmo-Smith RH, and Netter KJ (1975) Studies on the interaction of safrole with rat hepatic microsomes. Biochem Pharmacol 24:1427-1433.
8. Ellis JA (1984) Looking at kava as an export. Pacific Islands Monthly 55:27-28.
9. Guengerich FP (1995) Human cytochrome P450 enzymes, in Cytochrome P450 (Ortiz de Montellano P ed) pp 473-535. Plenum Press. New York.
10. Harris JW, Rahman A, Kim B-R, Guengerich FP, and Collins JM (1994) Metabolism of Taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54:4026-4035.
11. Hickman D. Wang JP, Wang Y, and Unadkat JD (1998) Evaluation of the selectivity of in vitro probes and suitability of organic solvents for the measurement of human cytochrome P450 monooxygenase activities. Drug Metab Dispos 26:207-215.
12. Hirota N, Ito K, Iwatsubo T, Green CE, Tyson CA, Shimada N, Suzuki H, and Sugiyama Y (2001) In vitro/in vivo scaling of alprazolam metabolism by CYP3A4 and CYP3A5 in humans. Biopharm Drug Dispos 22:53-71.
13. Hodgson E and Philpot RM (1974) Interaction of methylenedioxyphenyl (1.3-benzodioxole) compounds with enzymes and their effects on mammals. Drug Metab Rev 3:231-301.
14. Jellin JM, Gregory P, Batz F, Hitchens K, et al. (2002) Pharmacist's Letter/Prescriber's Letter Natural Medicines Comprehensive Database. Stockton, CA. Kava. http://www.naturaldatabase.com (Accessed July 23, 2002).
15. Jussofie A, Schmiz A, and Hiemke C (1994) Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) 116:469-474.
16. Keledjian J, Duffield PH, Jamieson DD, Lidgard RO, and Duffield AM (1988) Uptake into mouse brain of four compounds present in the psychoactive beverage kava. J Pharm Sci 77:1003-1006.
17. Kraft M, Spahn TW, Menzel J, Senninger N, Dietl KH, Herbst H, Domschke W, and Lerch MM (2001) [Fulminant liver failure after administration of the herbal antidepressant Kava-Kava]. Deutsch Med Wochenschr 126:970-972.
18. Laurenzana EM, Sorrels SL, and Owens SM (1995) Antipeptide antibodies targeted against specific regions of rat CYP2D1 and human CYP2D6. Drug Metab Dispos 23:271-278.
19. Lebot V and Lévesque J (1989) The origin and distribution of kava (Piper methysticum Forst. f. and Piper wichmannii C. DC., Piperaceae): A phytochemical approach. Allertonia 5:223-280.
20. Lebot V, Merlin M, and Lindstrom L (1992) Kava: The Pacific Drug, pp 57-81, Yale University Press, New Haven, CT.
21. Mathews JM, Etheridge AS, Raymer JH, Black SR, Pulliam DW Jr, and Bucher JR (1998) Selective inhibition of cytochrome P450 2E1 in vivo and in vitro with trans-1,2-dichloroethylene. Chem Res Taxicol 11:778-785.
22. Meyer HJ (1962) Pharmakologie der wirksamen prinzipien des kawa-rhizoms (Piper methysticum Forst. f.). Arch Int Pharmacodyn Ther 138:505-536.
23. Murray M and Reidy GF (1989) In vitro formation of an inhibitory complex between an isosafrole metabolite and rat hepatic cytochrome P-450 PB-B. Drug Metab Dispos 17:449-454.
24. Murray M, Wilkinson CF, Marcus C, and Dube CE (1983) Structure-activity relationships in the interactions of alkoxymethylenedioxybenzene derivatives with rat hepatic microsomal mixed-function oxidases in vivo. Mol Pharmacol 24:129-136.
25. Rasmussen AK, Scheline RR, Solheim E, and Hansel R (1979) Metabolism of some kava pyrones in the rat. Xenobiotica 9:1-16.
26. Rouse J (1998) Kava: A South Pacific herb for anxiety, tension and insomnia. Clin Nutri Insights 96:3900-3905.
27. Russmann S, Lauterburg BH, and Helbling A (2001) Kava hepatotoxicity. Ann Intern Med 135:68-69.
28. Ruze P (1990) Kava-induced dermopathy: A niacin deficiency? Lancet 335:1442-1445.
29. Schmider J, Brockmoller J, Arold G, Bauer S, and Roots I (1999) Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine. Pharmacogenetics 9:725-734.
30. Strahl S, Ehret V, Dahm HH, and Maier KP (1998) [Necrotizing hepatitis after taking herbal remedies]. Deutsch Med Wochenschr 123:1410-1414.